Petros Pharmaceuticals, INC

Petros Pharmaceuticals reports mutual separation with VP of Finance Mitchell Arnold and appoints Robert Weinstein as Chief Accounting Officer.

Petros Pharmaceuticals, Inc. announced the grant of 7,000,000 restricted common stock shares to key directors and officers.

Petros Pharmaceuticals, Inc. announced the grant of 7,250,000 restricted stock units to its Chairman, President, and two directors, with immediate and six-month vesting.

Petros Pharmaceuticals, Inc. received notice from Nasdaq regarding the delisting of its common stock, which will continue trading on the OTCID Basic Market.

Petros Pharmaceuticals, Inc. announced the dismissal of CBIZ CPAs P.C. and the appointment of HTL International, LLC as its new independent registered public accounting firm, effective August 29, 2025.

Petros Pharmaceuticals, Inc. announced the termination of its Stendra license agreement and the assignment of its Metuchen, Timm Medical, and Pos-T-Vac subsidiaries' assets for the benefit of creditors, leading to a significant restructuring and pro forma stockholders' equity of approximately $8.0 million.

Petros Pharmaceuticals, Inc. reported a significant accumulated deficit and substantial doubt regarding its ability to continue as a going concern in its latest quarterly filing.

Petros Pharmaceuticals reports a net loss of $0.99 million for Q1 2026 while continuing to navigate significant going concern risks.

Petros Pharmaceuticals reports significant Q3 losses, Nasdaq delisting, and a strategic pivot to an Rx-to-OTC self-care platform amid substantial doubt about its ability to continue as a going concern.

Petros Pharmaceuticals is transitioning its business focus to an Rx-to-OTC switch technology platform after discontinuing its previous product lines, while also navigating a delisting from Nasdaq and a going concern warning.

Petros Pharmaceuticals reports Q1 2025 results, highlighting a strategic shift towards self-care market innovation amidst ongoing financial and Nasdaq compliance challenges.

Petros Pharmaceuticals' Q3 2024 results reveal a net loss of $2.2 million and a decrease in revenue, alongside ongoing efforts to address financial instability and Nasdaq listing requirements.

Petros Pharmaceuticals has pivoted to a technology-focused business model following the insolvency of its legacy subsidiaries and the discontinuation of its Stendra product line.

Petros Pharmaceuticals discontinues Stendra sales and pivots towards developing a proprietary OTC technology platform while facing significant financial hurdles and going concern doubts.

Petros Pharmaceuticals has filed an amendment to its annual report to correct references to registration statements in the consents of its current and former independent accounting firms.

Petros Pharmaceuticals reports a net loss of $8.2 million for 2023 and expresses substantial doubt about its ability to continue as a going concern, despite efforts to expand Stendra sales and pursue OTC approval.

Director Wayne Remell Walker acquired 375,000 restricted shares of Petros Pharmaceuticals, Inc. common stock.

President and Chief Commercial Officer Fady Boctor acquired 375,000 restricted shares of Petros Pharmaceuticals common stock.

Director Bruce Bernstein acquired 1,875,000 restricted shares of Petros Pharmaceuticals, Inc. common stock.

Petros Pharmaceuticals director Joshua Silverman was granted 4,375,000 restricted shares of common stock.

Petros Pharmaceuticals' President & Chief Commercial Officer, Fady Boctor, acquired 500,000 Restricted Stock Units.

Petros Pharmaceuticals Director Joshua Silverman acquired 4,375,000 Restricted Stock Units, with a vesting schedule tied to continued service, adjusted for a recent reverse stock split.

Petros Pharmaceuticals is holding a special meeting to seek stockholder approval for several key proposals, including a share issuance related to recent warrants, a reverse stock split, and an amendment to their incentive compensation plan.

Petros Pharmaceuticals has hired Campaign Management LLC to solicit proxies for its upcoming annual meeting and corrected the vote count for its Series A Preferred Stock.

Petros Pharmaceuticals is holding its 2024 annual meeting of stockholders on November 20, 2024, to vote on key proposals including a reverse stock split, director elections, and executive compensation.

Petros Pharmaceuticals seeks to raise $1.6 million through a securities offering, including common stock, pre-funded warrants, and Series A and B warrants.

Petros Pharmaceuticals, Inc. is launching a securities offering amidst significant financial challenges, including ongoing losses, a going concern qualification, and a potential delisting from The Nasdaq Capital Market.

Petros Pharmaceuticals aims to raise up to $20 million through a unit offering to advance its platform for prescription-to-over-the-counter medication switches.

Petros Pharmaceuticals is seeking to raise up to $20 million through a unit offering to advance its proprietary platform aimed at facilitating the switch of prescription drugs to over-the-counter status.

Petros Pharmaceuticals is seeking to raise capital through a unit offering to fund its platform development and general corporate purposes, aiming to become a leader in the self-care market.

Iroquois Capital Management and its principals, Richard Abbe and Kimberly Page, reported a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc. as of December 21, 2025.

Iroquois Capital Management and its principals disclose a continued 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., limited by beneficial ownership blockers.

Iroquois Capital Management, LLC, along with its principals Richard Abbe and Kimberly Page, has disclosed a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., constrained by pre-existing beneficial ownership blockers on warrants and preferred shares.

Iroquois Capital Management, Richard Abbe, and Kimberly Page have filed a Schedule 13G, revealing a combined beneficial ownership of up to 9.99% in Petros Pharmaceuticals, Inc., subject to beneficial ownership blockers.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have disclosed a combined beneficial ownership of 6.2% in Petros Pharmaceuticals, Inc. common stock as of December 31, 2024.